Abstract: The present invention relates to a method for freezing and/or freeze-drying mitochondria isolated from cells, and a use of frozen and/or freeze-dried mitochondria. The frozen mitochondria according to the present invention showed similarity to non-frozen mitochondria in terms of anti-inflammatory activity and activity of energy metabolism-related enzymes. Also, the freeze-dried mitochondria showed similar levels of anti-inflammatory activity, activity of energy metabolism-related enzymes, and long-term preservation efficacy after recovery to those in the mitochondria before freeze-drying. Therefore, allowing isolated mitochondria to find a wide spectrum of applications in the treatment of various diseases caused by mitochondrial dysfunction or impairment, the frozen and/or freeze-dried mitochondria according to the present invention is expected to greatly enhance the commercial availability of therapeutics containing mitochondria.

Abstract: The present invention relates to a preservation solution composition for the preservation of an isolated cell, tissue, or organ, comprising isolated mitochondria; and a method for preserving an isolated cell, tissue, or organ by using the same. The preservation solution composition according to the present invention has excellent long-term preservability while maintaining the activity of isolated cell, tissue, or organ. Therefore, the present invention may be effectively used in the transplantation medicine field for ultimately improving transplant success rates and in the regenerative medicine field and the like.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating fibrosis and, more specifically, to a pharmaceutical composition for preventing or treating fibrosis, comprising mitochondria as an active ingredient. When the pharmaceutical composition of the present invention comprising exogenous mitochondria as an active ingredient is administered to a subject suffering from fibrosis such as pulmonary fibrosis, hepatic fibrosis and renal fibrosis, the fibrosis of tissues may be inhibited. In addition, the pharmaceutical composition of the present invention effectively inhibits the expression of fibronectin, CTGF2, ?-SMA, collagen 1A and the like during treatment of TGF-?. Therefore, the pharmaceutical composition according to the present invention may be effectively used in the prevention or treatment of fibrosis.

Abstract: The present invention relates to a mitochondrion containing a compound having the anticancer efficacy and uses thereof. It was confirmed that the mitochondrion efficiently deliver the compound to the tumor, and the anticancer effect of the mitochondrion containing the compound was confirmed. In particular, when an antibody or a fragment thereof that specifically binds to a tumor is bound to the surface of mitochondrion, the compound may be delivered specifically to the tumor. Therefore, the mitochondrion containing the compound according to the present invention may be effectively used for the treatment of cancer because the side effects of the compound are few.

Abstract: Provided herein are methods and compositions for treating a Nurr1-mediated and/or PPAR?-mediated condition. Also provided herein are methods and compositions for increasing Nurr1 or PPAR? activity and/or levels in a cell.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating fibrosis, containing a pheophorbide compound as an active ingredient. The pharmaceutical composition can effectively inhibit fibrosis of tissues by inhibiting signaling of TGF-? which causes fibrosis and inhibiting activation and expression of collagen and fibronectin, and is significantly superior in the anti-fibrotic activity compared to nintedanib or pirfenidone, which are commercially available therapeutic agents for pulmonary fibrosis, and therefore may be widely used in the prevention or treatment of fibrosis.

Abstract: The present invention relates to a pharmaceutical composition for the treatment of sepsis or systemic inflammatory response syndrome (SIRS) comprising mitochondria as effective ingredient. When activated macrophages and monocytes are treated with mitochondria which are effective ingredient of the pharmaceutical composition of the present invention, expression of IL-1?, TNF-? and IL-6 which are pro-inflammatory cytokines can be restored to normal levels. Furthermore, when the pharmaceutical composition of the present invention is administered to a subject suffering from sepsis, the survival rate of the subject can be remarkably increased. Therefore, the pharmaceutical composition according to the present invention can be useful for the treatment of sepsis.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating myositis. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating myositis, comprising mitochondria as an active ingredient. When the pharmaceutical composition of the present invention comprising exogenous mitochondria as an active ingredient is administered to a subject suffering from myositis, inflammatory cells infiltrated into the muscle cells of the subject can be reduced. In addition, the pharmaceutical composition of the present invention effectively inhibits the expression of IL-1?, TNF-?, and IL-6, inflammatory cytokines. Therefore, the pharmaceutical composition according to the present invention can be usefully used for preventing or treating myositis.

Abstract: Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome.

Abstract: Mitochondria modified by a targeting protein, according to one embodiment of the present invention, can be effectively delivered to a target. In addition, when a protein of interest bound to the modified mitochondria is delivered into a cell, various activities can be exhibited. The modified mitochondria can effectively cause cancer tissue death, and thus can also be used as an anticancer agent. Furthermore, various activities are exhibited according to a protein of interest loaded on modified mitochondria, and thus the modified mitochondria can be applied in the treatment of various diseases. Additionally, a fusion protein comprising a protein of interest and a fusion protein comprising a targeting protein, according to one embodiment of the present invention, can be used in order to modify mitochondria. Moreover, mitochondria modified with the fusion proteins exhibits various effects in a target cell.

Abstract: Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegenerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome.

Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of rheumatoid arthritis and, more particularly, to a pharmaceutical composition comprising mitochondria as an effective ingredient for prevention or treatment of rheumatoid arthritis. When a foreign mitochondria pharmaceutical composition of the present invention is administered to a subject suffering from rheumatoid arthritis, the subject may alleviate edema and rubefaction symptoms. In addition, the pharmaceutical composition of the present invention reduces an expression level of the inflammatory cytokine IL-6, but increases an expression level of the anti-inflammatory cytokine IL-10 in the subject. Therefore, the pharmaceutical composition according to the present invention can be effectively used for preventing or treating rheumatoid arthritis.

Abstract: Provided herein are methods and compositions for treating a Nurr1-mediated and/or PPAR-mediated condition. Also provided herein are methods and compositions for increasing Nurr1 or PPAR activity and/or levels in a cell.

Abstract: The present invention relates to a method for delivering exogenous mitochondria into cells and, more specifically, to a method for efficiently delivering, into the cytoplasm of target cells to be injected, mitochondria isolated from donor cells.

Abstract: Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegenerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome.

Abstract: Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating Parkinson's disease, which comprises, as an active ingredient, a Rhodotypos scandens extract obtained by extracting the stem of Rhodotypos scandens with an organic solvent, and a food additive showing the effect of preventing or treating Parkinson's disease, the food additive comprising Rhodotypos scandens extract as an active ingredient. The Rhodotypos scandens extracts of the present invention may prevent or treat Parkinson's disease without producing any particular side effects, and therefore can be widely used for more safely treating Parkinson's disease.

Abstract: The present invention relates to: a pharmaceutical composition or a Nurr1 activating composition for the prevention or treatment of a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the composition comprises an active ingredient in the form of genkwanin N or yuanhuacine, a Daphne genkwa extract comprising one or more of the above compounds, or a fraction thereof; or a functional food additive for preventing or alleviating a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the additive comprises genkwanin N or yuanhuacine, a Daphne genkwa extract comprising one or more of the above compounds, or a fraction thereof; and a method for the prevention or treatment of a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the method comprises the step of administering the pharmaceutical composition.

Abstract: Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating Parkinson's disease, which comprises, as an active ingredient, a Rhodotypos scandens extract obtained by extracting the stem of Rhodotypos scandens with an organic solvent, and a food additive showing the effect of preventing or treating Parkinson's disease, the food additive comprising Rhodotypos scandens extract as an active ingredient. The Rhodotypos scandens extracts of the present invention may prevent or treat Parkinson's disease without producing any particular side effects, and therefore can be widely used for more safely treating Parkinson's disease.